

- preparation for, 1821  
 timing of, 1821  
 in diabetes mellitus, 2426  
 for drug- and toxin-induced acidosis, 64e-9, 319  
 folate deficiency in, 647  
 for hypercalcemia, 314, 610, 2480t, 2481  
 for hyperkalemia, 312  
 for hypermagnesemia, 2463  
 oxalosis in, 2237  
 pericarditis in, 1575  
 for poisoning/drug overdose, 473e-7, 473e-8t, 473e-9t  
 for rewarming, 478e-3, 478e-3t
- Hemodynamic assessment  
 calculation and normal values, 1461t, 1748t, 1762t  
 in cardiac catheterization, 1461–1463  
 in cardiac tamponade, 1463t  
 in myocardial infarction, 1607, 1762t  
 normal waveforms, 1461t  
 in pericarditis, 1463t  
 in restrictive cardiomyopathy, 1463t  
 in shock, 1762t  
 in valvular heart disease, 1462, 1462f
- Hemoglobin, **631**  
 age-related changes in, 394t  
 biosynthesis of, 632–633  
 developmental biology of, 632  
 disorders of. *See* Hemoglobinopathies  
 electrophoresis of, 633, 634t  
 elevated, 399  
 functions of, 632  
 genetics of, 632–633  
 heme-heme interaction, 632  
 high-affinity, 636  
 increased, in hypoxia, 248  
 iron content of, 625t  
 in iron metabolism, 625  
 low-affinity, 636  
 in microcytic anemia, 628t  
 normal, 393, 394t, 2755t  
 oxygen-carrying capacity, 1748t  
 in pregnancy, 394t  
 reduced, in cyanosis, 248–249  
 structure of, 631, 631f  
 testosterone therapy and, 2372–2373
- Hemoglobin A, 631, 633  
 Hemoglobin A<sub>1c</sub> (HbA<sub>1c</sub>)  
 goals in diabetes, 2408t, 2410  
 goals in elderly, 82  
 reference values for, 2760t
- Hemoglobin A<sub>2</sub>, 631  
 Hemoglobin-based oxygen carriers (HBOC), 662  
 Hemoglobin C, 634, 636t  
 Hemoglobin C disease, 81e-4f  
 Hemoglobin E, 636t, 638–639  
 Hemoglobinemia, 81e-12f  
 Hemoglobin H disease, 638, 638t  
 Hemoglobin Kansas, 636, 636t  
 Hemoglobin Köln, 636t  
 Hemoglobin Lepore, 638  
 Hemoglobin M. Iwata, 636t
- Hemoglobinopathies, **633**  
 acquired, 633, 633t, 639  
 α-globin, 633  
 aplastic crisis in, 639  
 arthropathies associated with, 2242, 2242t  
 β-globin, 633  
 classification of, 633, 633t  
 detection and characterization of, 633–634, 636–637  
 epidemiology of, 633  
 genetic considerations in, 633  
 global considerations in, 633  
 with hemoglobins with altered oxygen affinity, 636, 636t  
 HSCT for, 139e-5  
 in pregnancy, 49  
 red cell indices in, 399  
 structural, 633t, 634, 634t. *See also* Sickle cell anemia
- thalassemias, 633, 633t. *See also* Thalassemia syndromes  
 with unstable hemoglobins, 636–637, 636t  
 Hemoglobin-oxygen dissociation curve, 247, 393, 632, 632f
- Hemoglobin S, 636t. *See also* Sickle cell anemia  
 Hemoglobin SC disease, 634t, 635
- Hemoglobinuria  
 march, 657, 657t  
 paroxysmal cold, 657t, 659  
 paroxysmal nocturnal. *See* Paroxysmal nocturnal hemoglobinuria
- Hemoglobin Yakima, 636, 636t  
 Hemojuvelin, 2515, 2515f
- Hemolysins, 145e-7
- Hemolysis  
 acute immune-mediated, 138e-3–4  
 compensated, 651  
 delayed immune-mediated, 138e-4  
 extravascular, 658, 659f  
 hyperbilirubinemia and, 2000  
 intravascular, 657t, 658
- Hemolytic anemia, **649**  
 acquired, 649t, 657, 657t  
 immune, 658, 658t  
 autoimmune hemolytic anemia, 377e-4, 658, 659f  
 cold agglutinin disease, 659  
 drug-induced, 658t  
 microangiopathic, 81e-4f, 282, 657, 657t, 726f  
 paroxysmal cold hemoglobinuria, 657t, 659  
 paroxysmal nocturnal hemoglobinuria. *See* Paroxysmal nocturnal hemoglobinuria  
 in infections, 657t, 658  
 from mechanical destruction of red cells, 657  
 microangiopathic, 657, 657t  
 from toxic agents and drugs, 659–660  
 in alcoholic liver disease, 2059  
 aplastic crisis in, 639  
 in babesiosis, 1385  
 bone marrow examination in, 81e-8f  
 chronic nonspherocytic, 656  
 clinical features of, 393, 399, 649–650, 649t  
 vs. compensated hemolysis, 650–651  
 diagnosis of, 399, 649–650, 649t  
 drug-induced, 39, 44  
 folate deficiency in, 647  
 in G6PD deficiency, 39t, 40  
 inherited, 649t  
 with cation transport disorders, 653, 653t  
 with enzyme abnormalities, 653–654, 654t  
 pyruvate kinase deficiency, 281, 650f, 653–654, 654t  
 familial hemolytic-uremic syndrome, 657  
 with red cell membrane-cytoskeleton abnormalities, 651, 653t  
 hereditary elliptocytosis, 652f, 653, 653t  
 hereditary spherocytosis. *See* Hereditary spherocytosis  
 with redox metabolism disorders, 654f, 657  
 glucose-6-phosphate dehydrogenase deficiency. *See* Glucose-6-phosphate dehydrogenase (G6PD) deficiency  
 pyrimidine-5'-nucleotidase (P5N) deficiency, 431e-5t, 431e-6f, 654t, 657  
 pathophysiology of, 650–651, 650f  
 peripheral blood smear in, 81e-4f  
 in sickle cell anemia, 634
- Hemolytic streptococcal gangrene. *See* Necrotizing fasciitis
- Hemolytic-uremic syndrome (HUS)  
 acute kidney injury in, 292, 1806t  
 after infectious diarrhea, 855t, 1864  
 atypical, 657, 730, 1832  
 in cancer, 1796  
 clinical features of, 133t, 1863  
 acute nephritis syndrome, 292  
 chemotherapy-related, 1796  
 jaundice, 282
- rash, 135  
 Shiga toxin-related, 1057  
 diagnosis of, 1807  
*E. coli* infections and, 267, 856, 1030, 1031, 1863  
 etiology of, 133t, 267  
 familial (atypical), 657, 1863  
 genetic considerations in, 1848  
 not associated with diarrhea, 730  
 pathogenesis of, 265e-2, 730, 1030, 1796, 1848, 1863  
 renal biopsy in, 62e-9f, 1848  
 Shiga toxin-related, 1057  
*Shigella* infections and, 1056–1057, 1864  
 in SLE, 2133–2134  
 vs. thrombotic thrombocytopenic purpura, 729, 1863  
 treatment of, 730, 1796–1797, 1848, 1864
- Hemophagocytic lymphohistiocytosis, 375e-2, 2112
- Hemophagocytic syndrome, 135e-4, 135e-9
- Hemophilia, **732**  
 arthropathy in, 2241–2242  
 autosomal, 731. *See also* von Willebrand disease  
 bleeding in, 403  
 carriers of, 735  
 clinical features of, 732–733  
 complications of, 734–735  
 diagnosis of, 733t  
 genetic considerations in, 732–733, 733t  
 pathogenesis of, 732–733  
 treatment of, 91e-3, 733t, 734
- Hemophilia A, 403, 437, 450t, 733. *See also* Hemophilia
- Hemophilia B, 450t, 733. *See also* Hemophilia
- Hemoptysis, **245**  
 in cancer, 1793–1794  
 etiology of, 245–246  
 evaluation of, 246–247, 246f  
 in lung cancer, 510, 510t  
 massive, 246  
 in mitral stenosis, 1540  
 in pulmonary embolism, 100  
 in respiratory disease, 1661  
 treatment of, 247  
 in tuberculosis, 1108
- Hemorrhage  
 anemia of, 662  
 epidural spinal, 2584  
 gastrointestinal. *See* Gastrointestinal bleeding  
 hypovolemia in, 298  
 intracranial. *See* Intracranial hemorrhage  
 retinal, 40e-2–3, 40e-2f, 40e-3f  
 splinter, 1443  
 subconjunctival, 199
- Hemorrhagic cystitis, 1208, 1798
- Hemorrhagic fever, viral. *See* Viral hemorrhagic fevers
- Hemorrhagic fever with renal syndrome, 1321
- Hemorrhagic telangiectasia, hereditary. *See* Osler-Weber-Rendu syndrome
- Hemorrhagic thrombocytopenia. *See* Essential thrombocytosis (ET)
- Hemorrhoidal cushions, 1976
- Hemorrhoidal disease, **1976**  
 classification of, 1976, 1976t  
 clinical features of, 1976–1977  
 diagnosis of, 1977  
 epidemiology of, 1976  
 etiology of, 273  
 at high altitudes, 476e-4  
 internal, endoscopic findings in, 1899, 1899f  
 pathophysiology of, 1976  
 treatment of, 1976t, 1977
- Hemorrhoidectomy, 1976t, 1977
- Hemosiderin, 346, 397, 2514
- Hemosiderosis, 639, 2514
- Hemostasis, **400**  
 antithrombotic mechanisms, 402  
 antithrombotic mechanisms in, 402f  
 disorders of, 403–404, 403t, 406t. *See also* specific disorders